US biopharma Vertex Pharmaceuticals (Nasdaq: VRTX) was trading nearly 2% higher during pre-market trading on Tuesday. This followed Vertex’ presentation of its third-quarter financial results and latest outlook for 2024 as a whole.
Product revenue rose by 12% compared to the same period of 2023, to $2.77 billion, beating the $2.68 billion expected by analysts, according to FactSet.
The growth was primarily driven by the continued strong performance of Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor), a fixed-dose combination medication used to treat cystic fibrosis. Its sales grew by 14% during the quarter, at nearly $2.59 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze